Roivant Sciences Ltd.
Financial highlights
| Metric | FY 03/31/26 | FY 03/31/25 | FY 03/31/24 | FY 03/31/23 | FY 03/31/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.3M | $29.1M | $32.7M | $31.5M | $55.3M |
| Selling, general & administrative | — | — | $687.4M | $600.5M | $775.0M |
| Research and development | $681.8M | $550.4M | $439.9M | $454.1M | $483.0M |
| Operating expenses | $1.3B | $1.1B | $884.1M | $938.3M | $1.4B |
| Operating income | -$515.1M | -$1.0B | $4.5B | -$906.8M | -$1.4B |
| Interest expense | — | — | $34.8M | $28.0M | $7.0M |
| Pretax income | -$264.6M | -$681.6M | $4.6B | -$885.0M | -$923.7M |
| Income tax expense | $133.3M | $48.2M | $21.5M | $4.1M | $369,000 |
| Net income | -$299.8M | -$172.0M | $4.3B | -$1.0B | -$845.3M |
| Balance Sheet | |||||
| Cash and equivalents | $1.4B | $2.7B | $6.5B | $1.7B | $2.1B |
| Current assets | $5.2B | $5.0B | $6.7B | $1.8B | $2.1B |
| Total assets | $5.7B | $5.4B | $7.2B | $2.4B | $2.6B |
| Current liabilities | $281.2M | $149.4M | $266.8M | $272.4M | $184.4M |
| Total liabilities | $416.3M | $249.7M | $774.0M | $782.0M | $523.7M |
| Stockholders' equity | $4.5B | $4.7B | $6.0B | $1.2B | $1.7B |
| Cash Flow Statement | |||||
| Cash from operations | -$750.3M | -$839.5M | -$765.3M | -$843.4M | -$677.7M |
| Depreciation and amortization | $3.3M | $14.1M | $22.0M | $18.9M | $5.9M |
| Stock-based compensation | $346.2M | $289.0M | $199.6M | $217.8M | $565.0M |
| Capital expenditure | $8.2M | $4.6M | $1.4M | $12.7M | $17.4M |
| Free cash flow | -$758.6M | -$844.0M | -$766.6M | -$856.1M | -$695.2M |
| Share repurchases | — | $1.3B | $0 | $0 | $2.2M |
| Impairments | $17.1M | — | — | — | — |
Shares outstanding 715.7M · Free float 38.6%
Annual filing data through FY ended March 31, 2026; float as of July 4, 2026.